Navigation Links
Gene therapy research switches off joint inflammation; switches on genetic process of joint repair

Underway

Dr. Mark J.S. Miller said that, "This trial is important because it directly compares Reparagen with glucosamine in treating subjects with moderate osteoarthritis. Glucosamine is both familiar to consumers and healthcare providers and is the primary natural product approach to osteoarthritis."

The double blind randomized controlled clinical trial will assess a variety of pain, mobility and functional assessments in subjects with moderate osteoarthritis of the knee. Prior to this clinical investigation Reparagen was found to be the first natural product to "silence" genes that promote joint damage while simultaneously activating the repair gene, IGF-1, in human chondrocytes.2

The clinical study being conducted by clinical research organization Santerra Pharmaceuticals, LLC (www.santerra-pharma.com) was submitted to Current Controlled Trials for review of the protocol and assignment of an International Standardized Randomized Controlled Trial Number (ISRCTN25438351).3

Rainforest Nutritionals, Inc. Vice President Paul Bobrowski emphasized that, "Reparagen continues to set a new standard in the joint health market, emphasized by this clinical study and the Current Controlled Trials validation." Elaborating Bobrowski said, "We believe that Reparagen’s unique mechanism of action and its NIH innovation Award makes it the alternative to glucosamine or chondroitin that consumers can trust and try".

Coauthor Paul Bobrowski emphasized that "If joints are like a brick wall made from bricks of glucosamine, and then it makes sense that to rebuild a functional wall that you need the master bricklayer and not just the simple approach of getting more bricks." Elaborating Bobrowski said, "By activating the joints master bricklayer Reparagen offers a more effective approach for regaining joint health."


'"/>

Source:nedelman@version.net


Page: 1 2

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... Wis. The mechanical force that a single fungal cell ... vanishingly small, but it plays a heavy role in setting ... In fact, it may not be too much of a ... land without the ability to respond to the touch of ... An, a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... (May 24, 2010) The timing of umbilical cord clamping ... suggest researchers at the University of South Florida,s Center of ... umbilical cord for a slightly longer period of time allows ... infant and, with that critical period extended, many good physiological ...
... , WALL, N.J. , May 24 BIO-key ... identification solutions, today announced that Evidian has integrated BIO-key,s biometric software ... deployed this biometric identification solution at two major pharmaceutical companies. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ...
... Israel Current research suggests that T helper-type ... actual inhibit the development of experimental immune encephalomyelitis (EAE), ... Th17 cells. The related report by Wildbaum et ... high CD4 + T cells restrain ...
Cached Biology News:Do we clamp the umbilical cord too soon? 2Do we clamp the umbilical cord too soon? 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 2BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 4When helper cells aren't helpful 2
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... market research report is available in its ... Market 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... Biodegradable materials are materials that are readily ... packaging differs from conventional non-degradable packaging in ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 27, 2014  Lisa Kulik saw fireworks for the ... holiday, thanks to a groundbreaking retinal implant co-invented by ... clinician-researcher at the University of Southern California (USC) Eye ... Peoria, Ariz. resident who has retinitis pigmentosa, ... sight. On June 2, she became the first person ...
(Date:8/27/2014)... 2014 Guggenheim Securities, the investment banking and ... hiring of veteran equity analyst Charles "Tony" Butler as ... will focus on the biotech/biopharma sector. " ... experience and a broad network of relationships in his ... and Head of Equities at Guggenheim Securities. "His insights ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
... Bulletin Board: GOVX), an Atlanta-based, publicly traded,biopharmaceutical company developing ... and other infectious agents, today,announced that its Corporate Presentation ... webcast live by Thomson Reuters. The Conference will be ... February 9 and 10, 2009. , ...
... Wis., Feb. 4 Mach One Corporation (Pink Sheets: ... develops biotechnology based solutions that produce positive, long term ... that it has signed a definitive agreement to acquire ... company that supplies ingredients to the food, feed and ...
Cached Biology Technology:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 2GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference 3Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc. 2
... HRP Stabilizing Diluent (MOPS Buffered) has been ... Peroxidase conjugates in solution. HRP Stabilizer ... maintains the conformation of the antibody or ... Product is filtered at 0.2 microns., ,Contents: ...
... products feature a dual strength adhesive system which ... use. The adhesives on either side of the ... adheres to the glass has an easy release ... coverslip, forms a stronger bond. This means that ...
... Life Science FLA-8000 Fluorescent Image Analyzer features ... single laser imaging system. This powerful new ... with fluorescent dyes or radioisotopes at resolutions ... laboratories. Speed, image quality and flexibility make ...
...
Biology Products: